Uncategorized Archives - Page 5 of 146

TuesdaySep 23, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) CEO Featured in BMW Podcast Discussing Breakthrough Breast CT Imaging

“Screening is the first line of defense,” said IZO CEO Robert Thast, who noted that company’s Breast CT technology can detect cancers as small as two millimeters. Thast summarized Izotropic’s recent advances in artificial intelligence. Company’s commercialization plans start in Europe and then expand to U.S, with focus on selling primarily to hospitals, medical facilities and imaging clinics. A new episode of the BioMedWire Podcast shines a spotlight on Izotropic (CSE: IZO) (OTCQB: IZOZF) and its innovative approach to breast cancer imaging. Featuring IZO CEO Robert Thast, the podcast (ibn.fm/JUWtD) reveals how Izotropic’s proprietary Breast CT technology could transform early…

FridaySep 19, 2025 10:30 am

Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum

CEO Dr. Vuong Trieu recognized as inventor of multibillion-dollar oncology assets, including Abraxane(R) and Cynviloq(TM) OTLC advancing late-stage pipeline led by OT-101 in Phase 3 for pancreatic cancer and multiple other high-unmet-need indications Recent progress includes 2 years of steady clinical and regulatory advancements across oncology and rare pediatric programs The biotechnology sector is defined by its ability to pair scientific innovation with leadership that can translate discoveries into approved therapies. This is particularly critical in oncology, where late-stage candidates must navigate complex regulatory pathways and demonstrate real clinical impact in indications with limited treatment options. Companies that combine robust…

WednesdaySep 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, adding urgency to the need for therapeutic innovation Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases This year, the company achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 combining Interleukin-2 In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC) is answering this call with pioneering RNA candidates and strategic programs aimed at…

TuesdaySep 16, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Clene Inc. reported new preclinical data on its drug candidate CNM-Au8 for Parkinson’s disease. The therapy improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized gene expression in dopaminergic neurons. Findings were presented at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City. CNM-Au8 previously showed positive energetic and metabolic effects in a Phase 2 Parkinson’s trial, aligning with the new preclinical results. The treatment demonstrated no toxicity in neuronal models, consistent with safety data from over 1,000 patient-years in ALS and MS trials. Clene plans to design a Phase 2 clinical study for Parkinson’s…

FridaySep 12, 2025 2:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage

Proprietary machine-learning reconstruction algorithm trained on 15 years of breast CT data positions IzoView to redefine global imaging standards Self-supervised approach works on X-ray data before reconstruction, avoiding the delays that cripple competing AI methods Trade secret protection and modality-specific training create durable competitive moats in a crowded, commoditized AI field The medical imaging industry stands at a pivotal juncture. Artificial intelligence promises to revolutionize diagnostics, yet most AI applications in CT imaging remain stuck in theory rather than practice. Conventional AI denoising tools either demand prohibitive computing power, compromise diagnostic clarity, or require impractical training datasets that increase patient…

FridaySep 12, 2025 12:30 pm

HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch

Company releases report updating status of proprietary 12-lead ECG synthesis software for arrhythmia assessment. Earlier this year, HeartBeam submitted its software application to the U.S. Food and Drug Administration. Plans will ensure that healthcare providers and patients can seamlessly integrate the HeartBeam system into clinical workflows and home-monitoring routines. In its most recent quarterly update, HeartBeam (NASDAQ: BEAT) is reporting that the company is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. The company is actively preparing for FDA 510(k) clearance of its innovative 12-lead ECG synthesis software for arrhythmia assessment while executing comprehensive commercial readiness…

ThursdaySep 11, 2025 12:45 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

Exclusive U.S. patent rights for computer-aided diagnosis (“CADx”) with breast CT secured through a global license with the University of California CADx planned as a post-market software upgrade, creating dual revenue streams via upgrade incentives and licensing Patent exclusivity paired with proprietary machine-learning reconstruction establishes a durable moat in dedicated breast imaging The AI Integration Challenge in Medical Imaging Artificial intelligence has long promised to revolutionize radiology, but most applications remain stuck between theoretical potential and real-world limitations. CADx systems can enhance detection, yet they face hurdles: lack of specialized datasets, workflow disruptions, and intellectual property barriers. In breast imaging,…

ThursdaySep 11, 2025 12:00 pm

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

Adageis provides AI-powered healthcare software designed to simplify value-based care adoption. The company’s patented ProActive Care Platform integrates with leading electronic health record (“EHR”) systems. The platform emphasizes simplicity, visibility into insurance contracts, and long-term financial gain for providers. Providers can use the system to identify high-value services, track reimbursements, and manage complex contracts. Adageis currently covers more than 260,000 patient lives, with ongoing growth expected. Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. By focusing on…

WednesdaySep 10, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System

The system’s design emphasizes user friendliness and portability while aligning with the growing trend toward remote patient monitoring and telemedicine. HeartBeam to initiate commercial launch upon FDA clearance of 12-lead ECG synthesis software, anticipated later this year. For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart's electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart's…

WednesdaySep 10, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) CEO Featured in BMW Podcast Discussing Breakthrough Breast CT Imaging

Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage

HeartBeam Inc. (NASDAQ: BEAT) Prepares Innovative ECG Technology for Commercial Launch

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search